Literature DB >> 24379304

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

H Ruth Ashbee1, Rosemary A Barnes, Elizabeth M Johnson, Malcolm D Richardson, Rebecca Gorton, William W Hope.   

Abstract

The burden of human disease related to medically important fungal pathogens is substantial. An improved understanding of antifungal pharmacology and antifungal pharmacokinetics-pharmacodynamics has resulted in therapeutic drug monitoring (TDM) becoming a valuable adjunct to the routine administration of some antifungal agents. TDM may increase the probability of a successful outcome, prevent drug-related toxicity and potentially prevent the emergence of antifungal drug resistance. Much of the evidence that supports TDM is circumstantial. This document reviews the available literature and provides a series of recommendations for TDM of antifungal agents.

Entities:  

Keywords:  fungal diseases; fungal pathogens; triazoles

Mesh:

Substances:

Year:  2013        PMID: 24379304      PMCID: PMC3977608          DOI: 10.1093/jac/dkt508

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  135 in total

1.  Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis.

Authors:  P Campoli; Q Al Abdallah; R Robitaille; N V Solis; J A Fielhaber; A S Kristof; M Laverdiere; S G Filler; D C Sheppard
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.

Authors:  F C Odds; F Van Gerven; A Espinel-Ingroff; M S Bartlett; M A Ghannoum; M V Lancaster; M A Pfaller; J H Rex; M G Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

3.  Voriconazole-associated severe hyponatremia.

Authors:  Kye-Hyung Kim; Seunghwan Lee; Shinwon Lee; Na Ra Yun; Nam Joong Kim; Kyung-Sang Yu; In-Jin Jang; Wan Beom Park; Myoung-Don Oh
Journal:  Med Mycol       Date:  2011-06-15       Impact factor: 4.076

4.  Population pharmacokinetics of voriconazole in adults.

Authors:  William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

5.  Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.

Authors:  Peter F Troke; Hans P Hockey; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

6.  Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring.

Authors:  Alexander Imhof; Dominik J Schaer; Urs Schanz; Urs Schwarz
Journal:  Swiss Med Wkly       Date:  2006-11-11       Impact factor: 2.193

7.  HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases.

Authors:  Carsten Müller; Margit Arndt; Christian Queckenberg; Oliver A Cornely; Martin Theisohn
Journal:  Mycoses       Date:  2006       Impact factor: 4.377

8.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of systemically administered antimycotics.

Authors:  Romuald Bellmann
Journal:  Curr Clin Pharmacol       Date:  2007-01

Review 10.  Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Authors:  Roger J M Brüggemann; Jan-Willem C Alffenaar; Nicole M A Blijlevens; Eliane M Billaud; Jos G W Kosterink; Paul E Verweij; David M Burger
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079

View more
  133 in total

1.  Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.

Authors:  Xuemei Wu; Raman Venkataramanan; Ryan M Rivosecchi; Chenxiao Tang; Rachel V Marini; Ryan K Shields; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring.

Authors:  Indy Sandaradura; Jessica Wojciechowski; Deborah J E Marriott; Richard O Day; Sophie Stocker; Stephanie E Reuter
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients.

Authors:  J M Boonstra; A G Märtson; I Sandaradura; J G W Kosterink; T S van der Werf; D J E Marriott; J G Zijlstra; D J Touw; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

4.  Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.

Authors:  Elodie Gautier-Veyret; Xavier Fonrose; Julia Tonini; Anne Thiebaut-Bertrand; Mireille Bartoli; Jean-Louis Quesada; Claude-Eric Bulabois; Jean-Yves Cahn; Françoise Stanke-Labesque
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

5.  Gastroesophageal Reflux Disease and Pulmonary Diseases Associated with Aspergillosis: Is There a Connection?

Authors:  Maria N Gamaletsou; David W Denning
Journal:  Mycopathologia       Date:  2017-07-12       Impact factor: 2.574

Review 6.  New facets of antifungal therapy.

Authors:  Ya-Lin Chang; Shang-Jie Yu; Joseph Heitman; Melanie Wellington; Ying-Lien Chen
Journal:  Virulence       Date:  2016-11-07       Impact factor: 5.882

7.  Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring.

Authors:  Pier Giorgio Cojutti; Maria Merelli; Lorenzo Allegri; Giuseppe Damante; Matteo Bassetti; Federico Pea
Journal:  Br J Clin Pharmacol       Date:  2018-11-09       Impact factor: 4.335

8.  Simultaneous quantitation of five triazole anti-fungal agents by paper spray-mass spectrometry.

Authors:  Christine L Skaggs; Greta J Ren; El Taher M Elgierari; Lillian R Sturmer; Run Z Shi; Nicholas E Manicke; Lindsey M Kirkpatrick
Journal:  Clin Chem Lab Med       Date:  2020-04-28       Impact factor: 3.694

9.  Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study.

Authors:  Pierre Peterlin; Cécile Chauvin; Steven Le Gouill; Morgane Pere; Marie Dalichampt; Thierry Guillaume; Alice Garnier; Maxime Paré; Amandine Le Bourgeois; Philippe Moreau; Patrice Chevallier; Guillaume Deslandes; Thomas Gastinne
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

10.  Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.

Authors:  Pier Giorgio Cojutti; Manuela Lugano; Elda Righi; Giorgio Della Rocca; Matteo Bassetti; William Hope; Federico Pea
Journal:  Eur J Clin Pharmacol       Date:  2018-07-21       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.